Exact Sciences Falls in After-Hours Trading on Q4 Results

Exact Sciences (NASDAQ:EXAS) released its results for the fourth quarter of 2020 after market close on Tuesday. Investors indicated their displeasure by trading the stock down.

For the period, the healthcare diagnostics specialist posted just over $466 million in revenue, which was nearly 58% higher on a year-over-year basis.